Supported by in-house scientists and first-in-class technological platforms, Creative Biolabs has expanded our service capabilities to offer fully integrated engineering ovarian cancer cells IGROV1 for self-destruction purposes to best suit the client's program requirements.

Background of Ovarian Cancer

Ovarian cancer is considered to be one of the leading causes of gynecological malignant tumor death in western countries. Statistics showed the yearly estimated incidence of up to 12 new cases per 100,000 women and 8 deaths per 100,000 women. In ovarian cancer, therapeutic management is used with a multidisciplinary approach, including debulking surgery, chemotherapy, as well as radiotherapy. In recent years, there has been an increasing interest in immunomodulatory therapy for OC. A novel therapeutic approach is exploring the use of cancer cells from the patient to deliver viruses to the tumor and tumor microenvironment which can be manipulated using cancer cells as virus carriers. This approach effectively turns "cold" cancer into "hot" cancer and increases the anti‐cancer response.

Fig.1 Emerging immunotherapies for ovarian cancer. (Chandra, et al., 2019)

Engineering Ovarian Cancer Cells IGROV1 for Self-destruction

The IGROV-1 cell line is established from a 47-year-old female patient with stage III ovarian solid primary tumor, which presents hypermutation and is characterized by the expression of vitronectin and αvα3 integrin, as well as the cancer-associated target MDM2. And it is regarded as a widely-used model for drug-resistant ovarian carcinoma. Leveraging our professional knowledge and experience, Creative Biolabs is committed to developing a new strategy for ovarian cancer immunotherapy research, providing engineering ovarian cancer cell line IGROV1 for self-destruction purposes to reduce the overall project development timeline for our clients.

We are proud to offer integrative research portfolio services for global customers to meet your research needs. Our services are characterized by:

• Flexible assay formats to meet diverse project needs.
• An excellent expert team for providing real-time technical guidance.
• Advanced and optimized assay platform to facilitate the data output.
• Customize experiment types according to customer needs to facilitate project progress.

Moreover, Creative Biolabs has expanded our service capabilities to offer a series of synthetic gene circuits relevant services, including but not limited to:

• Engineering Gastric Cancer Cells for Self-destruction
• Engineering Melanoma Cells for Self-destruction
• Engineering Neuroblastoma Cells for Self-destruction

Creative Biolabs offers high-quality integrative study assay portfolio services which will help our clients shorten the research journey. For more detailed information, please feel free to contact us or directly sent us an inquiry.

References

1. Chandra, A.; et al. Ovarian cancer: Current status and strategies for improving therapeutic outcomes. Cancer medicine. 2019, 8(16): 7018-31.
2. Montero, J.C.; et al. Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. Oncotarget. 2015, 6(30): 30057.

For Research Use Only | Not For Clinical Use